首页> 美国卫生研究院文献>The Journal of Molecular Diagnostics : JMD >Improved Detection of the KIT D816V Mutation in Patients withSystemic Mastocytosis Using a Quantitative and Highly Sensitive Real-Time qPCRAssay
【2h】

Improved Detection of the KIT D816V Mutation in Patients withSystemic Mastocytosis Using a Quantitative and Highly Sensitive Real-Time qPCRAssay

机译:改进的检测患者的KIT D816V突变。使用定量和高度敏感的实时定量PCR进行系统性细胞吞噬含量

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The vast majority of patients with systemic mastocytosis (SM) carry the somatic D816V mutation in the KIT gene. The KIT D816V mutation is one of the minor criteria for a diagnosis of SM according to the 2008 World Health Organization classification of myeloproliferative neoplasms. In the present study, we present a real-time qPCR assay that allows quantification of as little as 0.003% KIT D816V mutation-positive cells. A total of 61 samples from 31 cases of SM were included in the study. We detected the mutation in skin or bone marrow in 95% of the cases of SM. We demonstrate the clinical relevance of the assay by identifying as little as 0.03% mutation-positive cells in bone marrow aspirates from SM patients and calculate the analytical sensitivity of negative samples to determine the reliability of the result. We further demonstrate that this method also detects the KIT D816V mutation in peripheral blood in 81% of the mutation-positive cases with SM. The method also allows comparison of mutation-positive and mast cell fractions to determine whether the mutation is present in non-mast cells, a parameter that has recently been reported to be of prognostic importance in patients with indolent SM. Finally, the assay is suitable for use in prospective studies of the KIT D816V allele burden as a treatment endpoint inSM.
机译:绝大多数系统性肥大细胞增多症(SM)患者在KIT基因中携带体细胞D816V突变。根据2008年世界卫生组织对骨髓增生性肿瘤的分类,KIT D816V突变是诊断SM的次要标准之一。在本研究中,我们提出了一种实时定量PCR检测方法,该方法可定量低至0.003%的KIT D816V突变阳性细胞。来自31例SM的总共61个样本被纳入研究。我们在95%的SM病例中检测到皮肤或骨髓中的突变。我们通过在SM患者的骨髓穿刺物中鉴定出少至0.03%的突变阳性细胞,并计算阴性样品的分析灵敏度来确定结果的可靠性,从而证明该测定法的临床相关性。我们进一步证明,在81%的SM突变阳性病例中,该方法还可以检测外周血中的KIT D816V突变。该方法还允许比较突变阳性和肥大细胞部分,以确定突变是否存在于非肥大细胞中,最近已报道该参数对惰性SM患者的预后具有重要意义。最后,该测定法适合用于KIT D816V等位基因负荷作为前瞻性研究的前瞻性研究SM。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号